Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund Complete Calendar Year 2013 as WSJ Category Kings
BOSTON, MA (Marketwire Jan 21, 2014) The Eventide Gilead Fund’s no-load share class (NASDAQ: ETGLX) and the Eventide Healthcare & Life Sciences Fund’s no-load share class (NASDAQ: ETNHX) were both named as Category Kings by the Wall Street Journal for the one-year period ending December 31, 2013, in recognition of ranking within the top 10 funds in their categories (Midcap Growth and Health & Biotech, respectively) for total returns. The Eventide Gilead Fund finished the year ranked #3 out of 412 funds, and the Eventide Healthcare & Life Sciences Fund ranked #6 out of 87 funds.
The Eventide Funds are managed by Eventide Asset Management, LLC, a Boston-based investment advisor that practices values-based investing. For Eventide, values-based investing is a form of investing that seeks to partner with companies that create real value and blessing for their customers, employees, and other stakeholders. “We are pleased with the outperformance of both funds during the past year, as well as since the inception of these funds. We interpret the results as evidence that the principle of service above profits can potentially create reciprocal blessings for businesses and their shareholders,” said Eventide’s CEO, Robin John. “We strongly believe that value creation is the key indicator of business vitality and a reliable leading indicator of financial performance.
The Eventide Gilead Fund achieved a one-year total return of 52.93%, compared with the Russell Mid-Cap Growth Index return of 35.74% and S&P 500 Index return of 32.39%, outperforming each by 17.19% and 20.54%, respectively. The Eventide Healthcare & Life Sciences Fund achieved a one-year total return of 62.01%, compared with the Healthcare Blended Index return of 51.11% and S&P 500 Index return of 32.39%, outperforming each by 10.9% and 29.62%, respectively.
The following table outlines the Eventide Gilead Funds performance since inception:
|As of 12/31/2013||1 year return||3 year annualized return||5 year annualized return||Since inception (7/08/2008) annualized return|
|Eventide Gilead Fund*||52.93%||21.90%||25.67%||17.75%|
|S&P 500 Total Return Index||32.39%||16.18%||17.94%||9.43%|
|Russell Mid-Cap Growth Total Return Index||35.74%||15.63%||23.37%||10.89%|
The following table outlines the Eventide Healthcare & Life Science Fund’s performance since inception:
|As of 12/31/2013||3 months return||1 year return||Since inception (12/27/2012) annualized return|
|Eventide Healthcare & Life Sciences Fund*||3.37%||62.01%||61.65%|
|S&P 500 Total Return Index||10.51%||32.39%||32.74%|
|Healthcare Blended Index||10.89%||51.11%||51.23%|
Three-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investors shares, when redeemed, may be worth more or less than their original cost. Please review the funds’ prospectus for more information regarding the funds’ fees and expenses. Performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).
Eventide Gilead Fund Expenses ratios: Gross Expenses 1.75%; Net Expenses 1.64%. The advisor has agreed to maintain the Funds total annual operating expenses (excluding certain fees and expenses) at 1.42% at least until October 31, 2014.
Eventide Healthcare & Life Sciences Fund Expenses ratios: Gross Expenses 9.51%; Net Expenses 1.64%. The advisor has agreed to maintain the Funds total annual operating expenses (excluding certain fees and expenses) at 1.43% at least until October 31, 2014.
As of 12/31/2013, the Eventide Gilead Fund had $323,576,279.67 in net assets and the Eventide Healthcare & Life Sciences Fund had $39,745,499.32 in net assets.
Wall Street Journal rankings are not intended to constitute investment advice. As a result, you should not make an investment decision on the basis of this information. Rather, you should use the rankings for informational purposes only.
The S&P 500 is an index created by Standard & Poors Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid- cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The Healthcare Blended Index is composed of equal parts of the S&P 400 Healthcare Index and the S&P 600 Healthcare Index. These indexes are not investment products available for purchase.
Mutual Funds involve risk including the possible loss of principal. The Eventide Funds can invest in smaller- sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The funds can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The funds can have risk associated with a higher portfolio turnover, which could result in higher transactional costs. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.
An investor should consider the Funds investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about Eventide Funds can be found in the Funds prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836).
Eventide Funds is distributed by Northern Lights Distributors, LLC, member FINRA, which is not affiliated with Eventide Asset Management, LLC.